Medicine guide
Strimvelis
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence
- Made by
- Fondazione Telethon ETS
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available (see section 4.2 and section 4.4).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Fondazione Telethon ETS |
|---|---|
| Active substance | Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L03 · Cancer treatments and immune-system medicines |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2016-05-26 |
| Last updated by the regulator | 2026-05-08 |
| EMA product number | EMEA/H/C/003854 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).